Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,166,815 papers from all fields of science
Search
Sign In
Create Free Account
roscovitine
Known as:
(2R)-2-((6-benzylamino-9-(propan-2-yl)-9h-purin-2-yl)amino)butan-1-ol
, 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Broader (3)
Antineoplastic Agents
Protein Kinase Inhibitors
Purines
Narrower (3)
CYC 202
R-roscovitine
Seliciclib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Colon mustard oil instillation induced cross-organ reflex sensitization on the pelvic–urethra reflex activity in rats
H. Peng
,
Gin-Den Chen
,
+7 authors
Tzer-Bin Lin
Pain
2009
Corpus ID: 31483757
Highly Cited
2009
Highly Cited
2009
Seliciclib (CYC202, R‐roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model
M. Appleyard
,
M. O'Neill
,
+6 authors
Alastair M. Thompson
International Journal of Cancer
2009
Corpus ID: 25222163
We sought to determine whether seliciclib (CYC202, R‐roscovitine) could increase the antitumor effects of doxorubicin, with no…
Expand
Highly Cited
2005
Highly Cited
2005
Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells.
J. Węsierska-Gądek
,
Marieta Gueorguieva
,
M. Horký
Molecular Cancer Therapeutics
2005
Corpus ID: 8981299
We reported recently that roscovitine arrested human MCF-7 cancer cells at G2-M phase of the cell cycle and concomitantly induced…
Expand
Highly Cited
2005
Highly Cited
2005
Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.
B. Nutley
,
F. Raynaud
,
+7 authors
P. Workman
Molecular Cancer Therapeutics
2005
Corpus ID: 22216784
R-roscovitine (seliciclib, CYC202) is a cyclin-dependent kinase inhibitor currently in phase II clinical trials in patients with…
Expand
Highly Cited
2004
Highly Cited
2004
Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP
E. Kim
,
S. U. Kim
,
Deug Y. Shin
,
K. Choi
Oncogene
2004
Corpus ID: 8633097
The cytotoxic effect of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is limited in many glioma cell lines…
Expand
2003
2003
Involvement of the transcription factor E2F1/Rb in kainic acid-induced death of murine cerebellar granule cells.
Robert A. Smith
,
T. Walker
,
Xiaoqi Xie
,
S. Hou
Brain Research. Molecular Brain Research
2003
Corpus ID: 35033051
Highly Cited
2003
Highly Cited
2003
Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.
L. Maggiorella
,
E. Deutsch
,
+5 authors
J. Bourhis
Cancer Research
2003
Corpus ID: 32823840
Frequent deregulation of cyclin-dependent kinase (CDK) activation associated with loss of cell cycle control was found in most of…
Expand
Highly Cited
2002
Highly Cited
2002
Synthesis and biological activity of olomoucine II.
V. Kryštof
,
R. Lenobel
,
L. Havlícek
,
M. Kuzma
,
M. Strnad
Bioorganic & Medicinal Chemistry Letters
2002
Corpus ID: 29648980
Highly Cited
2001
Highly Cited
2001
Bovine oocytes treated prior to in vitro maturation with a combination of butyrolactone I and roscovitine at low doses maintain a normal developmental capacity
N. Ponderato
,
I. Lagutina
,
G. Crotti
,
P. Turini
,
C. Galli
,
G. Lazzari
Molecular Reproduction and Development
2001
Corpus ID: 24430534
Butyrolactone I (BL‐I) and Roscovitine (ROS), two specific and potent inhibitors of M‐phase promoting factor (MPF) kinase…
Expand
Highly Cited
2000
Highly Cited
2000
Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase.
A. Zimmermann
,
H. Wilts
,
M. Lenhardt
,
M. Hahn
,
T. Mertens
Antiviral Research
2000
Corpus ID: 19618701
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE